Skip to main content

Logo
  • Live News iconLive News
  • Smart Screener iconSmart Screener
  • Trade Opportunities iconTrade Opportunities
  • Alpha Watch iconAlpha Watch
  • Catalyst iconCatalyst
Skip to main content
Stock Ask Logo
Hi, Guest User

Log in or create an account to get full access

Open an Account (opens in a new window)

TOOLS

Live News
Smart Screener
Trade Opportunities
Alpha Watch
Catalyst

StockkASK powered by Indira Securities

Healthcare Global Enterprises Ltd (HCG) Share Price & Fundamentals

Company Overview

Founded Year

1998

Listed Year

2016

Headquarter

Bengaluru, Karnataka, India

MD/CEO

Leadership includes Dr. B.S. Ajaikumar

Website

https://www.hcgoncology.com

Company Facts

What we do

Healthcare Global Enterprises Ltd is India's largest private cancer care network providing comprehensive oncology and fertility services through its pan-India and African centers.

Founded in

1,998

Market share

Largest private cancer care provider in India with 22 comprehensive cancer centers and leading fertility clinics under Milann brand.

Problem solved

Addresses cancer and fertility treatment access by offering advanced clinical services, standardized protocols, and cutting-edge technologies across regions.

Top clients or who we serve

Serves cancer and fertility patients across India and Africa, primarily B2C with some institutional/private insurance partnerships.

Key management

Leadership includes Dr. B.S. Ajaikumar (Executive Chairman) and Dr. Manish Mattoo (CEO, appointed 2025).

Our journey and innovations

Founded 1998; IPO in 2016; introduced robotic surgery, Tomotherapy, MR-LINAC technology; expanded network with strategic acquisitions.

Where we operate

India across multiple cities and states, plus Kenya in Africa; expanding cancer and fertility care network.

Top products or what we offer

Comprehensive oncology care, fertility treatments, clinical lab diagnostics, molecular genetic testing, radiotherapy, surgery, chemotherapy.

Top brands

HCG – India’s largest private cancer care network; Milann – fertility centers; Triesta – oncology diagnostics.

Raw materials needed

-

Raw materials supplier

-

Recurring vs cyclical contribution

Revenue is largely recurring from ongoing patient treatments and diagnostic services with steady volume growth.

Our industry position

Market leader in private oncology care in India, with high clinical excellence and advanced technology adoption.

Financial highlights

FY25 revenue INR 2222 crore, PAT INR 44 crore (standalone); FY25 consolidated revenue INR 2223 crore; 16% yoy growth.

Geographical revenue split

~98% revenue from India; ~2% from international operations (Kenya).

Order book

-

Whats driving growth

Expanding cancer incidence, geographic network growth, technology adoption, improved operational efficiency, and brand strength.

Our future plans

New cancer centers including North Bangalore MR-LINAC facility, further network expansion, technology upgrades, and clinical research initiatives.

Our green promise

Committed to sustainability, digital reporting, and green initiatives including reduced paper use and carbon footprint awareness.

Our people and values

Diverse and highly skilled workforce with focus on clinical excellence, patient-centric care, and employee engagement.

Key challenges ahead

Managing capital expenditures, regulatory compliance, competitive landscape, and integration of acquisitions.

Interesting facts

First in India to introduce several advanced oncology technologies and largest private oncology network in terms of licensed centers.

Risks and strategy

Mitigates operational and market risks through standardized treatment protocols, technology upgrades, and disciplined capital allocation.

Market Footprint

Top Clients

Top Clients

Serves cancer and fertility patients across India and Africa, primarily B2C with some institutional/private insurance partnerships.

Top Products

Top Products

Comprehensive oncology care, fertility treatments, clinical lab diagnostics, molecular genetic testing, radiotherapy, surgery, chemotherapy.

Price Movement & Share Holding

Today's High/Low

581.65594.65

52 Week High/Low

513.3795.99
Past Returns

1 week

6.45%

1 month

-15.28%

3 month

-13.8%

1 year

-19.12%

3 year

64.26%

5 year

160.13%

Share Holding

Promoters

64.21%

FII

2.69%

DII

20.77%

Retail

10.73%

Others

1.59%

Company Overview

Founded Year

1998

Listed Year

2016

Headquarter

Bengaluru, Karnataka, India

MD/CEO

Leadership includes Dr. B.S. Ajaikumar (Executive Chairman) and Dr. Manish Mattoo (CEO

Website

https://www.hcgoncology.com

Price Movement & Share Holding

Today's High/Low

581.65594.65

52 Week High/Low

513.3795.99

Past Returns

1 week

6.45%

1 month

-15.28%

3 month

-13.8%

1 year

-19.12%

3 year

64.26%

5 year

160.13%

Share Holding

Promoters

64.21%

FII

2.69%

DII

20.77%

Retail

10.73%

Others

1.59%

Company Facts

What we do

Healthcare Global Enterprises Ltd is India's largest private cancer care network providing comprehensive oncology and fertility services through its pan-India and African centers.

Founded in

1998

Market share

Largest private cancer care provider in India with 22 comprehensive cancer centers and leading fertility clinics under Milann brand.

Problem solved

Addresses cancer and fertility treatment access by offering advanced clinical services, standardized protocols, and cutting-edge technologies across regions.

Top clients or who we serve

Serves cancer and fertility patients across India and Africa, primarily B2C with some institutional/private insurance partnerships.

Key management

Leadership includes Dr. B.S. Ajaikumar (Executive Chairman) and Dr. Manish Mattoo (CEO, appointed 2025).

Our journey and innovations

Founded 1998; IPO in 2016; introduced robotic surgery, Tomotherapy, MR-LINAC technology; expanded network with strategic acquisitions.

Where we operate

India across multiple cities and states, plus Kenya in Africa; expanding cancer and fertility care network.

Top products or what we offer

Comprehensive oncology care, fertility treatments, clinical lab diagnostics, molecular genetic testing, radiotherapy, surgery, chemotherapy.

Top brands

HCG – India’s largest private cancer care network; Milann – fertility centers; Triesta – oncology diagnostics.

Recurring vs cyclical contribution

Revenue is largely recurring from ongoing patient treatments and diagnostic services with steady volume growth.

Our industry position

Market leader in private oncology care in India, with high clinical excellence and advanced technology adoption.

Financial highlights

FY25 revenue INR 2222 crore, PAT INR 44 crore (standalone); FY25 consolidated revenue INR 2223 crore; 16% yoy growth.

Geographical revenue split

~98% revenue from India; ~2% from international operations (Kenya).

Whats driving growth

Expanding cancer incidence, geographic network growth, technology adoption, improved operational efficiency, and brand strength.

Our future plans

New cancer centers including North Bangalore MR-LINAC facility, further network expansion, technology upgrades, and clinical research initiatives.

Our green promise

Committed to sustainability, digital reporting, and green initiatives including reduced paper use and carbon footprint awareness.

Our people and values

Diverse and highly skilled workforce with focus on clinical excellence, patient-centric care, and employee engagement.

Key challenges ahead

Managing capital expenditures, regulatory compliance, competitive landscape, and integration of acquisitions.

Interesting facts

First in India to introduce several advanced oncology technologies and largest private oncology network in terms of licensed centers.

Risks and strategy

Mitigates operational and market risks through standardized treatment protocols, technology upgrades, and disciplined capital allocation.

Market Footprint

Top Clients

Top Clients

Serves cancer and fertility patients across India and Africa, primarily B2C with some institutional/private insurance partnerships.

Top Products

Top Products

Comprehensive oncology care, fertility treatments, clinical lab diagnostics, molecular genetic testing, radiotherapy, surgery, chemotherapy.

StockkASK provides smart, AI-powered insights to support analysis. AI can make mistakes; verify independently before investing.Terms & Conditions